October 28, 2008
Cortria Corporation’s TRIA-662 Named One of 10 Most Promising Cardiovascular Projects By Leading Industry Panel
Cortria Corporation, a clinical-stage pharmaceutical company focused on developing safe and well-tolerated medicines to fight cardiovascular disease, today announced that TRIA-662 has been selected as one of the Top 10 most promising cardiovascular projects in development. TRIA-662 is currently in Phase 2 clinical development for the treatment of dyslipidemia, an atherogenic disorder characterized by abnormal lipid levels in the bloodstream.
"We are excited that Windhover has selected TRIA-662 as one of the industry's top ten cardiovascular projects. This recognition supports our belief in the potential of TRIA-662 to become a new standard of care in the treatment of dyslipidemia by providing the benefits of niacin therapy without causing skin flushing," said Daniel Grau, CEO & Vice-Chairman of Cortria. "Skin flushing is a well-known side effect of niacin and severely limits use of available niacin-containing therapies."The selection of TRIA-662 was made by an independent committee of judges assembled by Windhover Information, a leading provider of business information products and services to senior executives in the pharmaceutical, biotechnology, and medical device industries.
"Selected companies have been screened using a strict set of judging criteria for the Top 10 award and represent what our committee considered the most attractive cardiovascular opportunities the industry has to offer," said Roger Longman, Managing Director of Windhover Information. "Winners have met rigorous criteria including: unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications, and corporate stability."
As a selected company, Cortria has been invited to present data on TRIA-662 at Windhover's Therapeutic Area Partnerships conference taking place November 3-5, 2008, in Philadelphia, PA.
TRIA-662 is currently in Phase 2 clinical development for the treatment of dyslipidemia, an atherogenic disorder characterized by abnormal fat levels in the bloodstream. In preliminary human studies, TRIA-662 demonstrated the potential to provide the lipid-controlling benefits of niacin therapy without causing skin flushing. Niacin was the first lipid-modifying agent proven in outcomes trials to extend life, yet the side-effects of niacin, principally skin flushing, cause many patients to discontinue therapy and substantially limit the drug's potential. Previous efforts to create a flush-free niacin therapeutic - using extended release formulations, dose titration and, more recently, fixed dose combination technologies - have not been successful. As a result, TRIA-662 represents an important opportunity as a new first-line therapy in the multi-billion dollar cardiovascular risk reduction market.
Cortria is a clinical-stage pharmaceutical company focused on developing safe and well-tolerated medicines to fight cardiovascular disease. Cortria is based in Boston, MA and backed by Domain Associates and MVM Life Science Partners.
Windhover Information Inc., an Elsevier company, has led the field in providing analysis of the healthcare industry to decision-makers at all levels since the founding of its flagship publication, IN VIVO, The Business & Medicine Report, in 1983. Windhover provides its information and analysis in many formats, including print, electronic databases, international conferences and webinars. For more on the company's products and services, please see www.windhover.com.
(c) 2008 Cortria Corporation. All rights reserved.